Want to see ACRV full AI Analyst Report?
ACRV Stock Chart & Stats
$1.78
-$0.20(-3.17%)
At close: 4:00 PM EST
$1.78
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.20 - $3.56
Previous CloseN/A
Volume1.72K
Average Volume (3M)440.12K
Market Cap
$74.48M
Enterprise Value$16.32M
Total Cash (Recent Filing)$97.74M
Total Debt (Recent Filing)$2.42M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 19, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding42,801,727
10 Day Avg. Volume666,765
30 Day Avg. Volume440,120
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit71.56
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$11.33Price Target Upside536.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Proprietary AP3 PlatformAcrivon's AP3 precision‑proteomics platform is a durable competitive asset: identifying responder subsets can improve trial outcomes, reduce development risk, and increase partner interest. Over months this supports higher probability of clinical success and more efficient resource allocation.
Low LeverageMinimal debt provides structural financial flexibility for a pre‑revenue biotech: lower refinancing risk and less fixed interest burden extend runway versus peers with higher leverage, enabling management to prioritize R&D and strategic partnerships over urgent debt servicing.
Shareholder & Governance SupportAnnual meeting approvals indicate shareholder backing of strategy and management continuity. Ratified auditor and newly elected directors support governance stability. Combined with an equity incentive framework, this helps attract and retain talent critical for long‑term drug development.
Bears Say
Pre‑revenue ProfileZero reported revenue and a pure development‑stage model mean value is tied entirely to successful clinical outcomes or partnering. This structurally increases funding reliance and execution risk over months, as operating performance cannot be supported by product cash flow.
Persistent Cash BurnConsistent, sizable negative free cash flow materially elevates the need for external financing. Recurrent burn compresses runway, forces fundraising cycles, and can dilute existing shareholders or constrain program investment choices, limiting strategic optionality.
Dilution & Equity Erosion RiskThe broadened equity plan institutionalizes potential future dilution while historical equity fell from ~$176.8M to ~$95.5M as losses mounted. Over the medium term, ongoing financing and automatic share increases can dilute ownership and raise the company's effective cost of capital.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.20 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $74.48M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 28 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.525 by $0.035.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.5.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 42,801,727 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.525. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (536.70% Upside)
$11.33 (536.70% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 22.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.85%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$11.33
▲(536.70% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
35.82% Insiders
2.57% Mutual Funds
0.03% Other Institutional Investors
59.22% Public Companies and Individual Investors